Future Ventures

Future Ventures is a financial services platform with a focus on disruptive technology companies such as commercial space exploration, deep learning, quantum computing, robotics, AI, blockchain, sustainable transportation, synthetic biology and clean meat. As venture capitalists, the founders of Future Ventures have led founding investments in several companies that had successful IPOs and others that were acquired for over $16 billion in aggregate. Some of our early VC investments include Memphis Meats, Mythic, Nervana, Planet, Rethink Robotics, Skype, SpaceX, Tesla and Zoox. Current board seats include SpaceX, Tesla, and D-Wave.

Steve Jurvetson

MD

34 past transactions

Taimei Medical Technology

Venture Round in 2020
Taimei Technology provides a cloud platform for clinical research collaboration. It is dedicated to propelling biopharmaceutical industry development through technology with a focus in the field of clinical research and pharmacovigilance. Taimei Technology cloud platform was designed for clinical research collaboration between sponsors, sites, CROs, patients, regulatory agencies and third-party providers. Its platform offers 6 technology-enabled solutions encompassing data management, project management, electronic regulatory submission, central medical imaging, pharmacovigilance, and drug logistics. Its clients include pharmaceutical enterprises, CRO and research institutes. The company was founded in 2013 and is headquartered in Jiaxing, Zhejiang, China.

New Culture Inc.

Series A in 2021
New Culture Inc. produces cheese from protein. The company uses microflora to make dairy proteins and dairy products. New Culture Inc. was founded in 2019 and is based in San Leandro, California.

medcorder

Seed Round in 2019
Medcorder, Inc. develops medcorder, a mobile application that allows its users to record and transcribe complete conversations with their doctor and then share them with their family. Its application helps patients and their families to better communicate and coordinate care. The company's application also helps doctors by reducing the number of calls and repeated visits they get. The company’s application is compatible with Android and iOS. The company was founded in 2019 and is headquartered in Redwood City, California.

Mobilecoin, Inc.

Series A in 2021
MobileCoin combines privacy, security, and distributed trust with a great user experience. MobileCoin is designed so that a mobile messaging application like WhatsApp, Facebook Messenger, or Signal could integrate with a MobileCoin wallet.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.
Commonwealth Fusion Systems LLC develops energy through inexhaustible power plant. The company uses rare-earth barium copper oxide superconductor technology to develop energy. It offers fusion energy to combat climate change. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

ATAI Life Sciences AG

Series C in 2020
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering with mental health disorders. We are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. By pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based therapies.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.

Deep Genomics Inc.

Series B in 2020
Deep Genomics Inc., an artificial intelligence (AI) therapeutics company, develops individualized genetic medicines by creating AI systems that are used to accelerate various steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment, and innovative trial design. It develops and markets therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders. The company develops oligonucleotide therapies that target the genetic determinants of disease at the level of RNA or DNA. Deep Genomics Inc. was founded in 2014 and is based in Toronto, Canada.

Alice Technologies

Series B in 2022
ALICE empowers construction engineering and management professionals with modern AI and Optimization techniques. Its software automatically produces detailed schedules and resource allocations, which accurately estimate the cost and time frame for a project. Users understand the construction process through an interactive visualization, and can quickly tweak or modify a schedule to reflect the shifting realities of the construction cycle. It is born out of research at Stanford by a collaborative effort between experienced construction managers, software engineers, and computational methods specialists. ALICE enhances construction planning and scheduling abilities to help keep crews flowing on any size project. It works directly with 3D BIM and using a simple rule-based system, it explores millions of different schedule sequences and gives teams the power to answer “What If?” scenarios and completely reschedule in just minutes. It was founded in 2013 and is headquartered in Menlo Park, California.

Osmind

Series B in 2022
Osmind builds software for clinics that care for treatment-resistant mental health patients. Our software and insights improve clinical care and streamline provider workflows, while accelerating the development of novel therapeutics, precision diagnostics, and care management programs. Osmind's mission is to maximize patient access to innovative mental health treatments that can help where other therapies fail. The company was founded in 2020 and operates in Mountain View, California.

64-x

Series A in 2022
64-x designs microorganisms with enhanced properties that enable otherwise unattainable applications in biomanufacturing, bioremediation, and health. Alexis Rovner, George Church, Jeffrey Way, and Pamela Silver founded 64-x on August 22, 2017. 64-x is based in San Francisco, CA.

Ockam Inc.

Series A in 2022
Ockam Inc. provides a server less platform for secure Internet-of-things (IOT) development. The company’s tool enables to interconnect hardware with software services and facilitate the exchange of information within connected systems; manage identities, cryptographic keys, and credentials for devices and services; and optimize connectivity and messaging for the exchange of information between entities and applications. Additionally, it connects application developers and system integrators; hardware and chipset engineers; and cloud service product managers. Ockam Inc. was founded in 2017 and is headquartered in San Francisco, California.

Osmind

Series A in 2021
Osmind builds software for clinics that care for treatment-resistant mental health patients. Our software and insights improve clinical care and streamline provider workflows, while accelerating the development of novel therapeutics, precision diagnostics, and care management programs. Osmind's mission is to maximize patient access to innovative mental health treatments that can help where other therapies fail. The company was founded in 2020 and operates in Mountain View, California.

Cambrian BioPharma

Series B in 2021
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.

Capital Technologies

Series A in 2021
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Cambrian BioPharma

Series C in 2021
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.

Latent AI

Series A in 2021
Latent AI, Inc. develops a platform for optimization for edge devices that enables smart Internet of things (IoT) applications. It offers Latent AI Efficient Interence Platform (LEIP) that enables developers to train, quantize, and deploy edge AI neural networks. The company’s LEIP is designed for AI, embedded, and software application developers to enable, deploy, and manage AI for the edge. Latent AI, Inc. was incorporated in 2018 and is based in Menlo Park, California. It has additional office in Skillman, New Jersey.

Cambrian BioPharma

Venture Round in 2021
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.

Faeth Therapeutics

Seed Round in 2022
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.

Cambrian BioPharma

Series B in 2021
Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.
YourChoice Therapeutics, Inc. develops and manufactures non-hormonal contraceptive product for women. The company develops a technology with active compound which inhibits sperm motility and prevents sperm from fertilizing the egg. YourChoice Therapeutics, Inc. was founded in 2018 and is headquartered in Berkeley, California.
Sensei Biotherapeutics, Inc. develops precision cancer therapeutics that target a tumor-specific antigen (aspartate ß-hydroxylase). It offers various cancer immunotherapies, such as cancer vaccines and T-cell therapies for cancer patients. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is based in Gaithersburg, Maryland with an additional office in Boston, Massachusetts.

The Boring Company

Venture Round in 2019
The Boring Company is an infrastructure and tunnel construction company that aims to dig tunnels efficiently to facilitate an underground transportation network. The company was founded by Elon Musk in late 2016.
Commonwealth Fusion Systems LLC develops energy through inexhaustible power plant. The company uses rare-earth barium copper oxide superconductor technology to develop energy. It offers fusion energy to combat climate change. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Capital Technologies

Seed Round in 2020
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Mythic

Series B in 2019
Mythic Inc. designs and develops silicon chips and intelligence processing unit (IPU) based on artificial intelligence (AI). Its AI platform puts desktop GPU compute capabilities and neural networks onto a button-sized chip. The company was formerly known as Isocline Engineering Corporation. Mythic Inc. was founded in 2012 and is based in Redwood City, California with an additional office in Austin, Texas.

Ockam Inc.

Seed Round in 2019
Ockam Inc. provides a server less platform for secure Internet-of-things (IOT) development. The company’s tool enables to interconnect hardware with software services and facilitate the exchange of information within connected systems; manage identities, cryptographic keys, and credentials for devices and services; and optimize connectivity and messaging for the exchange of information between entities and applications. Additionally, it connects application developers and system integrators; hardware and chipset engineers; and cloud service product managers. Ockam Inc. was founded in 2017 and is headquartered in San Francisco, California.

Latent AI

Seed Round in 2019
Latent AI, Inc. develops a platform for optimization for edge devices that enables smart Internet of things (IoT) applications. It offers Latent AI Efficient Interence Platform (LEIP) that enables developers to train, quantize, and deploy edge AI neural networks. The company’s LEIP is designed for AI, embedded, and software application developers to enable, deploy, and manage AI for the edge. Latent AI, Inc. was incorporated in 2018 and is based in Menlo Park, California. It has additional office in Skillman, New Jersey.

Capital Technologies

Seed Round in 2019
Hum Capital is the funding platform that connects great companies with the right capital. Hum offers companies raising up to $50 million the most efficient, transparent path to growth. Hum’s Intelligent Capital Market uses AI to translate volumes of a company’s financial data into the clearest picture of their value, so they can fundraise with confidence, on the best terms for their business. Investors on Hum’s platform gain investment insights and a personalized deal flow built on company data they can trust. For more information, visit HumCapital.com.

Alice Technologies

Debt Financing in 2020
ALICE empowers construction engineering and management professionals with modern AI and Optimization techniques. Its software automatically produces detailed schedules and resource allocations, which accurately estimate the cost and time frame for a project. Users understand the construction process through an interactive visualization, and can quickly tweak or modify a schedule to reflect the shifting realities of the construction cycle. It is born out of research at Stanford by a collaborative effort between experienced construction managers, software engineers, and computational methods specialists. ALICE enhances construction planning and scheduling abilities to help keep crews flowing on any size project. It works directly with 3D BIM and using a simple rule-based system, it explores millions of different schedule sequences and gives teams the power to answer “What If?” scenarios and completely reschedule in just minutes. It was founded in 2013 and is headquartered in Menlo Park, California.